Changqing Li1, Weihua Jia2, Jian Li1, Fangfei Li1, Jing Ma3, Lichun Zhou4. 1. Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. 2. Department of Neurology, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing, China. 3. Department of Echocardiography, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China. 4. Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. zhlc8888@hotmail.com.
Abstract
BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. CYP2C19 polymorphisms resulted in individual differences in clopidogrel response. Our objective was to determine whether elderly stroke patients aged over 75 years would benefit from CYP2C19-genotype-guided strategy for the secondary prevention of stroke. METHODS: A retrospective analysis of patients aged 75 years or older with non-cardiogenic stroke who received 75 mg clopidogrel was performed. CYP2C19 genotype-guided group included noncarriers of CYP2C19*2 or CYP2C19*3 loss-of-function alleles (LoFA) and compared against the non-genotype-guided group which may carriers CYP2C19 LoFA or not. The primary endpoints were composite of stroke and myocardial infarction at 24 months' follow-up. RESULTS: Two hundred one patients were included: 99 in the genotype-guided group and 102 in the non-genotype-guided group. Kaplan-Meier(KM)analysis showed that CYP2C19 gene polymorphism was associated with the rate of the primary endpoints (P = 0.0031). The primary endpoints occurred in 13 patients (13.1%) in the genotype-guided group and in 30 patients (29.4%) in the non-genotype-guided group (hazard ratio(HR), 0.39; 95% confidence interval(CI), 0.20 to 0.75; p = 0.004). Cox regression analysis showed that CYP2C19 genotype-guided strategy was a protective factor for the primary endpoints (HR, 0.39; 95% CI:0.20 to 0.74, P = 0.004). CONCLUSION: The CYP2C19 genotype-guided strategy could reduce the occurrence of composite of stroke and myocardial infarction compared to a non-genotype-guided strategy for non-cardiogenic stroke patients aged 75 years or older who received clopidogrel.
BACKGROUND:Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. CYP2C19 polymorphisms resulted in individual differences in clopidogrel response. Our objective was to determine whether elderly strokepatients aged over 75 years would benefit from CYP2C19-genotype-guided strategy for the secondary prevention of stroke. METHODS: A retrospective analysis of patients aged 75 years or older with non-cardiogenic stroke who received 75 mg clopidogrel was performed. CYP2C19 genotype-guided group included noncarriers of CYP2C19*2 or CYP2C19*3 loss-of-function alleles (LoFA) and compared against the non-genotype-guided group which may carriers CYP2C19 LoFA or not. The primary endpoints were composite of stroke and myocardial infarction at 24 months' follow-up. RESULTS: Two hundred one patients were included: 99 in the genotype-guided group and 102 in the non-genotype-guided group. Kaplan-Meier(KM)analysis showed that CYP2C19 gene polymorphism was associated with the rate of the primary endpoints (P = 0.0031). The primary endpoints occurred in 13 patients (13.1%) in the genotype-guided group and in 30 patients (29.4%) in the non-genotype-guided group (hazard ratio(HR), 0.39; 95% confidence interval(CI), 0.20 to 0.75; p = 0.004). Cox regression analysis showed that CYP2C19 genotype-guided strategy was a protective factor for the primary endpoints (HR, 0.39; 95% CI:0.20 to 0.74, P = 0.004). CONCLUSION: The CYP2C19 genotype-guided strategy could reduce the occurrence of composite of stroke and myocardial infarction compared to a non-genotype-guided strategy for non-cardiogenic strokepatients aged 75 years or older who received clopidogrel.
Authors: Daniel M F Claassens; Gerrit J A Vos; Thomas O Bergmeijer; Renicus S Hermanides; Arnoud W J van 't Hof; Pim van der Harst; Emanuele Barbato; Carmine Morisco; Richard M Tjon Joe Gin; Folkert W Asselbergs; Arend Mosterd; Jean-Paul R Herrman; Willem J M Dewilde; Paul W A Janssen; Johannes C Kelder; Maarten J Postma; Anthonius de Boer; Cornelis Boersma; Vera H M Deneer; Jurriën M Ten Berg Journal: N Engl J Med Date: 2019-09-03 Impact factor: 91.245
Authors: Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Joseph R Walker; Tabassome Simon; Elliott M Antman; Eugene Braunwald; Marc S Sabatine Journal: Lancet Date: 2010-10-16 Impact factor: 79.321
Authors: Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: Christian Weimar; Hans-Christoph Diener; Mark J Alberts; P Gabriel Steg; Deepak L Bhatt; Peter W F Wilson; Jean-Louis Mas; Joachim Röther Journal: Stroke Date: 2008-11-20 Impact factor: 7.914
Authors: Sang Won Han; Yong-Jae Kim; Seong Hwan Ahn; Woo-Keun Seo; Sungwook Yu; Seung-Hun Oh; Hyo Suk Nam; Hye-Yeon Choi; Sung Sang Yoon; Seo Hyun Kim; Jong Yun Lee; Jun Hong Lee; Yang-Ha Hwang; Kee Ook Lee; Yo Han Jung; Jun Lee; Sung-Il Sohn; Youn Nam Kim; Kyung-A Lee; Cheryl D Bushnell; Kyung-Yul Lee Journal: J Stroke Date: 2017-09-29 Impact factor: 6.967